Status:
TERMINATED
Transcranial Magnetic Stimulation for Focal Hand Dystonia
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Dystonia
Eligibility:
All Genders
18-70 years
Brief Summary
Background: * The brain has natural electrical rhythms of brain activities. These rhythms may be different in people with movement disorders, such as dystonia (involuntary muscle movement, cramps, or...
Detailed Description
Objectives: The purpose of this protocol is to improve understanding of the pathophysiology of dystonia by performing an electrophysiological study using transcranial magnetic stimulation (TMS). The ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Confirmed diagnosis of focal hand dystonia (patients only).
- Between age 18 and 70 years.
- Able to give informed consent
- Right handed
- Agrees to not drink caffeine or alcohol for 48 hours before study session.
- No open scalp wounds or scalp infections.
- EXCLUSION CRITERIA:
- Has used illegal drugs within the past 6 months based on history, including but not limited to marijuana, cocaine, methamphetamine, etc. The intent is to exclude those with drug use that may affect study results. Participants who appear to be intoxicated at the time of testing will be rescheduled.
- Has more than 7 alcoholic drinks a week in the case of a woman and 14 alcoholic drinks a week in the case of a man.
- Abnormal findings on neurologic exam (other than dystonia in patient group)
- Has had a brain tumor, a stroke, traumatic brain injury, epilepsy or a history of seizures.
- Has major depression or any major mental disorders (axis I disorders)
- Has a neurologic disorder other than dystonia
- Has had a head injury where there was a loss of consciousness for more than a few seconds.
- Has a pacemaker, intracardiac lines, implanted pumps or stimulators, or has metal objects inside the eye or skull. Dental fillings and dental braces are allowed.
- Has known hearing loss.
- Pregnancy
- Taking any medication that acts as a central nervous system stimulant or that is known to lower seizure threshold, including, imipramine, amitriptyline, doxepine, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, (MDMA, ecstasy), phencyclidine (PCP, angel s dust), ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline, mianserin, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, reboxetine, venlafaxine, duloxetine, bupropion, mirtazapine, fluphenazine, pimozide, haloperidol, olanzapine, quetiapine, aripiprazole, ziprasidone, risperidone, chloroquine, mefloquine, imipenem, penicillin, ampicillin, cephalosporins, metronidazole, isoniazid, levofloxacin, cyclosporin, chlorambucil, vincristine, methotrexate, cytosine arabinoside, BCNU, lithium, anticholinergics, antihistamines, and sympathomimetics.
- Has excessive daytime sleepiness as indicated by a score of 10 or higher on the Epworth Sleepiness Scale.
Exclusion
Key Trial Info
Start Date :
February 13 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 19 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01792336
Start Date
February 13 2013
End Date
February 19 2019
Last Update
December 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892